This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.


  Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Aug. 9, 2012

   Home   Mission/Vision    Membership    Corporate Membership    CME/CEU    JMCM    Contact Us

Click Here to view the Journal of Managed Care Medicine

Online CME/CEU Programs
Multiple Myeloma: An Update on Diagnostic and Treatment Strategies

Advanced Treatment of Osteoporosis in Postmenopausal Women

Decreasing the Cost Burden of Fibromyalgia with Early Diagnosis and Management


Announcing the NAMCP Medical Directors Lung Cancer Resource Center. Click here to visit the website.

Be sure to check out the study results of Verinata's Non-Invasive Prenatal Technology. Click here to view the press release.

Click here to check out the "Latest in Clinical Nutrition" DVD available for purchase now!

Fall Managed Care Forum
November 8-9
Bellagio Hotel

 



 Genomics

Study: Fainting may have a genetic link
CNN    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Maybe it's the sight of blood, or standing too much, or pain, or scary thoughts — in any of these cases, you might find yourself alert one second and unconscious the next. About 25 percent of people will faint during their lifetime. The technical term for fainting, when it happens because of an environmental trigger, is "vasovagal syncope." The process involves a drop in blood pressure. A new study in the journal Neurology suggests that there is a genetic component to fainting. More



Bracing for the next wave of sports cheats: Genetic dopers
The Globe and Mail    Share    Share on FacebookTwitterShare on LinkedinE-mail article
So far, those trying to convince athletes they know the secret of gene doping are selling the sizzle, not the steak. But the steak is coming, and anti-doping experts are wrestling with the ethical dilemma of how to deal with athletes who are genetically modified or adept. More

Now Hiring! Disability Examination Providers

The VA Locum Tenens Program seeks physicians and psychologists to perform disability examinations for general medicine and mental health conditions. Physicians will provide compensation and pension examinations for Veterans who file for disability claims. This position requires extensive travel around the country. Compensation package includes salary and full travel. Send your CV to locumtenens@va.gov or contact us at 1-866-664-1030.


University oversees cutting-edge trial to fight Lou Gehrig's disease
Detroit Free Press    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A clinical trial overseen by the University of Michigan may provide hope. It is cutting-edge and audacious work — the only ALS trial so far in which neural stem cells are injected directly into a patient's spinal cord. So far, 15 patients have undergone the procedure — two of them twice — as the FDA monitors its safety. One patient showed a remarkable improvement for a while, though U-M's Dr. Eva Feldman, who heads the research, cautions not to read too much into that. The other 14 showed no improvement. More

 Biotech/Diagnostics/Personalized Medicine


Research on pain drugs seeks genetic-trait link
The Wall Street Journal    Share    Share on FacebookTwitterShare on LinkedinE-mail article
An international research team is launching an ambitious effort to determine whether everyday painkillers like Celebrex and Aleve could be made safer and more effective through personalized medicine, which involves tailoring treatments to patients based on genetic traits. More

CARDIODX®

Your patient's blood doesn't tell you that they will get tired walking the dog. Or that they've had heartburn for the past 2 weeks. But it can tell you whether or not obstructive CAD is what's causing their symptoms. You may not need to go deeper than the blood to know what's happening. MORE


Lower risk of serious side effects in trials of new targeted drugs
Medical Xpress    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis. More


Nursing@
Georgetown


Nursing@Georgetown is a Master’s in Nursing program delivered online by Georgetown University’s renowned School of Nursing & Health Studies.
MORE
Our activities touch many lives
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. We discover, develop, manufacture and market prescription medicines for cancer, cardiovascular, gastrointestinal and infection. MORE


 Regenerative Medicine


The FDA wants to regulate your cells
The Wall Street Journal    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A recent decision by a federal trial court gave the Food and Drug Administration the latitude that the agency has long sought to regulate our cells as drugs. It could put the brakes on one of the most promising areas of medical research. At issue are cells taken from our own bodies and then re-implanted with the purpose of treating medical problems. More

Spray-on skin cells heal wounds fast
MedPage Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Spray-on skin cells significantly improved wound healing versus standard care in patients with venous leg ulcers, results of a randomized trial showed. The best results occurred with the lowest dose of spray-on cells, which resulted in complete healing in almost a third more patients as compared with the placebo group. More

 Emerging Medical Technologies


Gearing up for the next big steps in robotic surgery
Business Insider    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Robotic surgery, the amazing technology that allows surgeons to operate on patients with greater efficiency and precision via a surgeon-controlled robotic device, is poised to change the nature of surgery forever. More

Girl gets 3-D-printed robotic arm
Laboratory Equipment    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Stratasys released a case study demonstrating how 3-D printing helped 4-year-old Emma Lavelle overcome the limitations of a congenital disorder, allowing her to use her arms for the first time. Using a Dimension 3-D printer, researchers at the Alfred I. duPont Hospital for Children in Philadelphia were able to create what Emma calls her "magic arms." The device is a custom-designed robotic exoskeleton that enables her to conquer greatly limited joint mobility and underdeveloped muscles. More

 Managed Healthcare News


Medical malpractice cap is struck down by Missouri Supreme Court
St. Louis Post-Dispatch    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The Missouri Supreme Court struck down a $350,000 limit on jury awards for "pain and suffering" in medical malpractice cases, saying the law violates a patient's right to a jury trial. The cap on malpractice awards was established by a 2005 state law as part of a "tort reform" push. More

Puzzling over what to call state insurance exchanges
The Wall Street Journal    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Health-insurance exchanges are a central part of President Barack Obama's health overhaul, serving as marketplaces for people to shop for coverage. But states trying to set them up are finding many people don't know what an exchange is and don't necessarily like the sound of it. As many as 25 million people are supposed to gain coverage through the exchanges over the next decade, according to the latest Congressional Budget Office estimate. More

 FDA: New Treatments and Technology


Analysis: Failed Alzheimer's drug may get 2nd chance
Reuters    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Pfizer and Johnson & Johnson's Alzheimer's drug failed to help patients showing early signs of the disease, but it could get another chance as scientists test whether the devastating illness should be treated before symptoms appear. Pfizer and J&J said they were scrapping large-scale clinical trials of the experimental drug bapineuzumab in patients with mild to moderate Alzheimer's disease, after the drug failed to improve their memory or thinking skills. More

FDA approves generic version of Singulair
Reuters    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The Food and Drug Administration said it granted 10 drugmakers marketing approvals for the first generic forms of Singulair, the $5 billion-a-year asthma and allergy drug that is Merck & Co's best-selling product. The drugmakers, whose cheaper versions of Singulair are expected to quickly steal two-thirds of the branded product's sales, include Mylan Inc., Teva Pharmaceutical Industries Ltd. and the Sandoz division of Novartis AG. More

FAST FACTS
"Generally, fainting is more common in older people, according to the National Institutes of Health. Among the causes are heat or dehydration, stress or a drop in blood sugar."
 

Genomics Biotech and Emerging Medical Technologies Institute eBrief
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Christine Kraly, Content Editor, 469.420.2685   
Contribute news

This edition of the Genomics Biotech and Emerging Medical Technologies Institute eBrief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!
Recent issues
Aug. 2, 2012
July 26, 2012
July 19, 2012
July 12, 2012



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063